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Abstract
Background and Purpose—The mechanism underlying the association of atrial fibrillation
(AF) with cognitive decline in stroke-free individuals is unclear. We examined the association of
incident AF with cognitive decline in stroke-free individuals, stratified by subclinical cerebral
infarcts (SCIs) on brain MRI scans.
Methods—We analyzed data from 935 stroke-free participants (mean age±SD, 61.5±4.3 years;
62% women; and 51% black) from 1993–1995 through 2004–2006 in the Atherosclerosis Risk in
Communities Study, a biracial community-based prospective cohort study. Cognitive testing
(including the Digit Symbol Substitution [DSS] and the Word Fluency [WF] test) was performed
in 1993–1995, 1996–1998, and 2004–2006, and brain MRI scans in 1993–1995 and 2004–2006.
Results—During follow-up, there were 48 incident AF events. Incident AF was associated with
greater annual average rate of decline in DSS (−0.77; 95% CI, −1.55 to 0.01; P=0.054) and WF
(−0.80; 95% CI, −1.60 to −0.01; P=0.048). Among participants without SCIs on brain MRI scans,
incident AF was not associated with cognitive decline. In contrast, incident AF was associated
with greater annual average rate of decline in WF (−2.65; 95% CI, −4.26 to −1.03; P=0.002)
among participants with prevalent SCIs in 1993–1995. Among participants who developed SCIs
during follow-up, incident AF was associated with a greater annual average rate of decline in DSS
(−1.51; 95% CI, −3.02 to −0.01; P=0.049).
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Conclusions—The association of incident AF with cognitive decline in stroke-free individuals
can be explained by the presence or development of SCIs, raising the possibility of anticoagulation
as a strategy to prevent cognitive decline in AF.
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Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and its prevalence
is increasing over time.1, 2 AF is associated with an increased risk of stroke,3 heart failure,4
and death.5–7 Evidence is emerging that AF is also associated with another growing public
health problem, namely, cognitive impairment or dementia. Earlier studies have shown that
the evidence for the association between AF and dementia is strongest in individuals with
prevalent stroke; 8–10 in the broader population, the evidence is less clear.11–13 A meta-
analysis reported a 2.4-fold increase in the odds of dementia associated with AF when
restricted to patients with stroke.14 For studies in the broader population, the association
between AF and dementia is of borderline significance with substantial heterogeneity in the
risk estimates.14 Later studies, however, provided evidence that AF is associated with
cognitive impairment or dementia even in individuals without clinical stroke. Kalantarian et
al. reported in a meta-analysis that AF was associated with an increased risk of cognitive
impairment and dementia, with or without a history of clinical stroke.15 In addition, recent
reports from the Cardiovascular Health Study16 and ONTARGET and TRANSCEND
studies17 indicated that in the absence of clinical stroke, participants with AF experienced
faster cognitive decline than those without AF. Although compelling, the mechanism
underlying the association between AF and cognitive decline or dementia in the absence of
clinical stroke was not elucidated in the aforementioned studies. Understanding the
mechanism underlying the association between AF and cognitive decline or dementia in
stroke-free individuals is critical in informing prevention strategies for cognitive decline in
these individuals.
Based on a previous report that 14.7% of patients with AF had silent cerebral infarcts on
cranial CT scans,18 we hypothesized that incident AF is associated with greater cognitive
decline in individuals without clinical stroke via SCIs. To test our hypothesis, we evaluated
in a stroke-free population the association between incident AF and rate of cognitive
decline, stratified by the presence or absence of subclinical cerebral infarcts (SCIs) on brain
MRI scans. We tested our hypothesis in the Atherosclerosis Risk in Communities (ARIC)
Study, a large USA community-based cohort study of cardiovascular disease.
METHODS
Study Population
The ARIC cohort is a biracial population-based sample from 4 communities in North
Carolina, Mississippi, Minnesota, and Maryland, consisting of 15792 men and women, and
45–64 years of age at baseline or visit 1 (1987–1989).19 After the visit 1 examination, there
were 3 additional exams: visit 2 (1990–1992), visit 3 (1993–1995), and visit 4 (1996–1998).
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Cognitive assessments were performed in the entire ARIC cohort at visit 2 (n=14128) and
visit 4 (n=11093). Of the 6715 participants who returned for ARIC visit 3 (1993–1995) at 2
ARIC Field Centers (i.e., Forsyth County, NC, and Jackson, MS), 2891 participants aged 55
years and older were invited for brain MRI scan and cognitive assessment (Figure I, online
supplement). Usual safety exclusion criteria for MRI excluded 2% of women and 6% of
men; brain MRI studies and cognitive assessments were performed in 1920 and 2053
participants, respectively, at visit 3. All participants with MRI scanning at visit 3 were
invited to undergo another brain MRI scan and cognitive assessment in 2004–2006; 1129
and 1097 participants completed brain MRI scan and cognitive assessment, respectively, in
2004–2006 (Figure I, online supplement). We included in our analysis cohort, participants
who had cognitive assessments performed at visit 3, visit 4, 2004–2006, and brain MRI
studies at visit 3 and 2004–2006 (n=1024). Therefore, visit 3 (1993–1995) was the baseline
of our analysis and the follow-up was through 2004–2006. After exclusions, the final
analysis cohort comprised 935 participants. Figure II in the online supplement shows the
exclusion criteria and the final number of participants enrolled in the analysis cohort.
The ARIC Study protocol was approved by the institutional review board of each
participating center and informed consent was obtained from each study participant.
Ascertainment of Atrial Fibrillation
AF diagnoses were obtained from ECGs at 4 study visits and hospital discharge records
through December 31, 2009.20 Hospitalizations in ARIC are identified by participant or
proxy report in the annual follow-up and by surveillance of local hospital discharge lists. All
ECG recordings automatically coded as AF were visually rechecked by a cardiologist to
confirm the diagnosis.21 A trained abstractor obtained and recorded all International
Classification of Diseases, Ninth Revision (ICD-9) hospital discharge diagnoses from each
hospitalization. AF was defined as the presence of ICD-9 code 427.31 or 427.32 in the
discharge codes. By physician review of 125 discharge summaries with ICD codes
indicating possible AF, we confirmed the presence of AF in approximately 90%.20
Ascertainment of Ischemic Stroke
Prevalent stroke at ARIC visit 1 was defined as a self-reported history of physician-
diagnosed stroke. To identify incident stroke, cohort participants were followed over time
through annual telephone interviews, triennial field center examinations, surveillance of the
ARIC community hospitals for all cohort members’ hospitalizations, and the review of death
certificates, physician questionnaires, coroner/medical examiner reports, and informant
interviews. Hospital reports were reviewed for evidence of acute stroke if the discharge
diagnosis included a cerebrovascular disease code (ICD-9 codes 430 to 438), if a
cerebrovascular procedure was mentioned in the summary, or if the CT or MR report
showed evidence of cerebrovascular disease. Medical records for potential stroke events
were forwarded to a single nurse abstractor at a central ARIC office who abstracted each
record for number, type, and severity of neurological deficits and supporting angiographic,
CT, MRI, spinal tap, or autopsy evidence. ARIC adapted National Survey of Stroke criteria
for its stroke definition.22 A computerized algorithm and physician reviewer independently
confirmed the diagnosis of stroke with disagreements adjudicated by a second physician
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reviewer. Stroke cases were further classified as definite versus probable and into further
subtypes as embolic versus thrombotic stroke.23 For this study, incident ischemic stroke
included definite or probable ischemic strokes (embolic or thrombotic).
Cognitive Testing
Cognitive assessments, baseline performance, and longitudinal characteristics of the
cognitive assessment battery have been previously reported.24, 25 This battery included the
Delayed Word Recall (DWR) Test, the Digit Symbol Substitution (DSS) Subtest of the
Wechsler Memory Scale-Revised, and the first-letter Word Fluency (WF) Test. Details of
the tests are presented in the Supplemental Methods in the online supplement.
Brain MRI
The ARIC Study MRI screening protocol and image analyses have been previously
described.26 Briefly, 1.5 T magnetic resonance scanners (GE and Picker) were used. Axial
images were angled to be parallel to the anterior commissure–posterior commissure line.
The digital scan images, including SD/T2 weighted (3000, 30–100, TR, and TE) and T1
weighted images, were evaluated at the MRI Reading Center on a Vortech Personal Display
System (PDS-4) workstation. The image evaluation was conducted by trained and certified
MRI readers. SCIs were defined as focal, non-mass lesions ≥3 mm that were bright on T2
and proton density, and dark on T1 images. All scans were subjected to double-reads for
infarct scoring.
Covariates
Definitions of covariates are presented in the Supplemental Methods in the online
supplement.
Statistical Analysis
We report means with standard deviations (SDs) or medians and interquartile ranges (IQR)
for continuous variables and counts with percentages for categorical variables.
To test the association between AF and cognitive decline rate, we used mixed-effects linear
models (PROC MIXED). The models consisted of AF status, time of follow-up (in years),
and a term for the interaction of AF x time. Participants who developed incident stroke after
visit 3 were excluded from the analysis. Model 1 was adjusted for age, sex, race, and
interaction terms: age x time, sex x time, and race x time. Model 2 was additionally adjusted
for field center, educational level (<high school, completed high school, some college), and
time-varying smoking status (current, not current), body mass index, hypertension, diabetes,
coronary heart disease (CHD), and heart failure. The coefficient for time estimates the
average annual rate of change in the cognitive test score, and the coefficient for the
interaction term (AF x time) estimates the difference in average annual rate of change
associated with the presence of AF.
To determine whether the association between AF and cognitive decline is mediated by
SCIs, we performed 3 additional analyses. First, we repeated the analysis in participants who
did not have SCIs at both visit 3 and in 2004–2006. Second, we evaluated the association
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between incident AF and cognitive decline rate in participants with prevalent SCIs at visit 3.
Third, we evaluated the association between incident AF and cognitive decline rate in
participants without SCIs at visit 3 and who developed SCIs by 2004–2006.
Finally, to further evaluate whether SCIs mediate the cognitive decline associated with AF,
we conducted a secondary analysis by assessing the association of prevalent or incident SCIs
with change in cognitive scores, stratified by presence or absence of incident AF.
Statistical analysis was performed using SAS version 9.2 (SAS Institute Inc., Cary, NC). All
P values reported were 2-sided, and statistical significance threshold was chosen as 5%.
RESULTS
Study Population
The analysis cohort consisted of 935 participants (mean age, 61.5 [SD, 4.3] years at
baseline; 62.0% women; 50.7% black). During a median (IQR) follow-up of 10.6 (9.8–11.2)
years, 48 participants developed AF. Compared with participants who did not develop AF,
there were more men and whites among participants who developed AF. Participants who
developed AF were also older and had higher prevalence of current smoking, hypertension,
and CHD. Table 1 shows the baseline characteristics of study participants.
Table I in the online supplement stratifies participants with AF by CHA2DS2–VASc score
and describes the proportion of participants with AF who were anticoagulated. Of 48
participants with AF, 28 (58.3%) had CHA2DS2–VASc score ≥2, meeting definite criteria
for anticoagulation. The rate of anticoagulation, however, was very low even among
participants with CHA2DS2–VASc score ≥2. Of 48 participants with incident AF, 20
(41.7%) had a CHADS2 score of 0, 23 (47.9%) had a score of 1, and 5 (10.4%) had a score
of ≥2. Therefore, based on CHADS2 score, 89.6% of participants had CHADS2 score <2 and
would not have met definite criteria for anticoagulation.
Atrial Fibrillation and Cognitive Decline
Table II in the online supplement shows the summary cognitive test scores of study
participants at visit 3, visit 4, and 2004–2006. Participants who developed AF had greater
annual average rate of decline in DSS (−0.77; 95% CI, −1.55 to 0.01; P=0.054) and WF
(−0.80; 95% CI, −1.60 to −0.01; P =0.048) than those who did not develop AF (Table 2).
Incident AF was not associated with a greater rate of decline in DWR.
To evaluate whether or not incident AF is associated with greater cognitive decline in the
absence of SCIs, we repeated the analysis restricting to participants who did not have SCIs
at both visit 3 and 2004–2006. In this subset comprising 699 participants of whom 29
developed AF, incident AF was not associated with decline in all 3 cognitive test scores
(Table 3).
Next, we evaluated the association of incident AF and cognitive decline in participants who
had prevalent SCIs at visit 3. There were 67 participants in this subset of whom 3 developed
AF. In this subset, compared with participants who did not develop AF, participants who
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developed AF had greater annual average rate of decline in WF (−2.65; 95% CI, −4.26 to
−1.03; P =0.002) but not in DWR and DSS (Table 4).
Finally, we evaluated the association of incident AF and cognitive decline in participants
who did not have SCIs at visit 3 but developed them by 2004–2006. In this subset
comprising 169 individuals, participants who developed AF (n=16) had greater annual
average rate of decline in DSS (−1.51; 95% CI, −3.02 to −0.01; P=0.049) than those who
did not develop AF. Incident AF was not associated with decline in DWR or WF (Table 5).
Risk Factors and Impact of Subclinical Cerebral Infarcts
Table III in the online supplement shows selected baseline characteristics (at Visit 3) of
participants without prevalent or incident SCIs vs. those with prevalent or incident SCIs.
The distribution of stroke risk factors was not significantly different between the 2 groups
with the exception of hypertension and AF; the prevalence of hypertension and AF
incidence were significantly higher among participants with prevalent or incident SCIs.
Further, in participants with incident AF, the proportion who developed SCIs was 16 of 48
(33.3%); this proportion was almost double that in participants without incident AF, 153 of
887 (17.3%). Table IV in the online supplement shows the number (%) of participants with
SCIs on their brain MRI scans at ARIC visit 3 and 2004–2006. Collectively, the data suggest
that AF is an important risk factor for SCIs.
To further evaluate whether SCIs mediate the cognitive decline associated with AF, we
conducted a secondary analysis. In this secondary analysis, we assessed the association of
prevalent or incident SCIs with change in cognitive scores, stratified by presence or absence
of incident AF. We found that compared with absence of prevalent or incident SCIs,
presence of prevalent or incident SCIs was significantly associated with greater decline in
DSS, even in participants without AF (Table 6). This observation suggests that it is not AF
per se, but rather SCIs that are related to cognitive decline.
DISCUSSION
In a large biracial population-based cohort study that comprised middle-aged individuals, we
observed that participants without clinical stroke who developed AF had greater cognitive
decline compared with participants who did not develop AF. However, this association was
true only in participants who had prevalent SCIs or who developed SCIs during follow-up.
In individuals without prevalent SCIs or who did not develop SCIs during follow-up,
incident AF was not associated with cognitive decline. Further, prevalent or incident SCI
was significantly associated with greater cognitive decline, even in the absence of AF.
Collectively, our observations suggest that the association between incident AF and
cognitive decline is mediated by the presence or development of SCIs.
A recent meta-analysis of 21 studies has provided compelling evidence for an association
between AF and cognitive impairment or dementia.15 AF was significantly associated with
an increased risk of cognitive impairment in patients with first-ever or recurrent stroke
(relative risk [RR], 2.70; 95% CI, 1.82–4.00) and in a broader population including patients
with or without a history of stroke (RR, 1.40; 95% CI, 1.19–1.64). Of note, among studies
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that excluded patients with prevalent stroke or adjusted the risk estimates for prevalent
stroke, AF was also significantly associated with an increased risk of cognitive impairment
(RR, 1.34; 95% CI, 1.13–1.58). However, the possibility of silent stroke or SCIs as the
mechanism underlying the association in patients without clinical stroke cannot be excluded.
The findings of our study are consistent with the recent meta-analysis above15 and recent
reports from the Cardiovascular Health Study,16 ONTARGET and TRANSCEND studies,17
and provide further evidence that incident AF is associated with dementia or cognitive
decline in individuals without stroke. The VA Stroke Prevention in Nonrheumatic AF
Investigators reported that 14.7% of patients with AF had silent cerebral infarcts on cranial
CT scans.18 Further, from a recent case-control study by Gaita et al., silent cerebral ischemia
was reported to be more prevalent in patients with AF than in controls, and cognitive
performance was worse in patients with AF than in controls.27 However, the study did not
demonstrate that the worse cognitive performance in patients with AF was mediated by
silent cerebral ischemia. Based on the findings of the VA study and the study by Gaita et al.,
we hypothesized that incident AF may be associated with greater cognitive decline in
individuals without clinically manifested stroke via SCIs. To test our hypothesis, we
performed additional analyses stratified by the presence or absence of SCIs as determined by
brain MRI scans. In individuals without SCIs, incident AF was not associated with cognitive
decline. By way of contrast, in participants with prevalent SCIs or who developed SCIs
during follow-up, incident AF was related to greater rate of cognitive decline. Thus, the
association between AF and cognitive decline can be explained by the presence or
development of SCIs.
The majority of SCIs in our study were likely deeply located in the deep nuclear region and
deep cerebral white matter.28 Nevertheless, these lesions could still be related to AF. The
VA Stroke Prevention in Nonrheumatic AF Investigators reported in a study of 516 patients
with AF who underwent cranial CT scans that 46 of 76 (61%) patients with SCIs had lesions
that were small and located in the deep hemispheric areas that are typically classified as
lacunar infarcts.18 Therefore, SCIs that are related to AF are not exclusively located
superficially; they can also be deeply located.
Cognitive decline associated with AF was reflected in a greater annual average change in
DSS and WF, but not DWR. The pattern of cognitive decline is worth noting. In general,
DWR is a test of recent memory, DSS is a test of attention, and WF is a test of executive
function. In participants with prevalent SCIs, incident AF was associated with a greater
decline in executive function (WF), whereas in participants who developed SCIs during
follow-up, incident AF was associated with a greater decline in attention (DSS). The ARIC
study had previously reported that over a 14-year follow-up (visit 2 through 2004–2006),
diabetes was associated with a decline in DSS and WF, hypertension was associated with a
decline in WF, and systolic blood pressure was related to a decline in DSS.29 The APOE ε4
genotype–most strongly associated with the risk of Alzheimer’s disease–was associated with
declining performance in DWR.29 These patterns are consistent with a model of
pathoanatomic relationships where lacunar infarcts30 and vascular risk factors31, 32 are
associated with attentional and executive function deficits, whereas Alzheimer’s disease-
related risk is associated with decline in memory functioning.33, 34 These data suggest that
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although SCI may be the principal mechanism that mediates cognitive decline associated
with AF, the possible contribution of other shared risk factors (e.g., hypertension) cannot be
entirely excluded.
The strengths of this study include the long follow-up, inclusion of black participants, and
extensive measurement of covariates. However, several limitations should be noted. First,
incident AF was identified mostly from hospitalization discharges and we could have missed
asymptomatic AF or AF managed exclusively in an outpatient setting. However, we and
others have previously shown that the validity of AF ascertainment using hospitalizations is
acceptable,20, 35 that incidence rates of AF in ARIC are consistent with other population-
based studies,20, 35 and that the associations between genetic variants in the chromosome
4q25 locus and AF–extremely specific for AF risk–in ARIC are similar to other studies with
a more rigorous ascertainment of AF.36 Second, we defined SCIs as focal, non-mass lesions
≥3 mm that were bright on T2 and proton density, and dark on T1 images. Therefore,
participants with SCIs <3 mm might have been misclassified. Third, ARIC participants who
failed to complete the 11 years of observation (ARIC visit 3 through 2004–2006) because of
death, an inability to undergo MRI, or refusal had greater burdens of disease (e.g., diabetes,
hypertension), lower baseline cognitive test scores and worse baseline MRI findings than
those who completed follow-up. Therefore, participants who completed the longitudinal
assessments described here comprised the healthier subset of the original cohort. Because of
the loss to follow-up of participants with more disease burden and cognitive impairment at
baseline, we may have underestimated the degree of cognitive decline during the 11 years of
observation. However, we do not expect this loss to follow-up to introduce a substantial bias
on the assessment of the association between AF and cognitive decline because in all our
analyses we have adjusted for determinants of participation in the follow-up exams (e.g.,
diabetes, hypertension, coronary heart disease, and others). Fourth, since we are unable to
classify AF type (paroxysmal, persistent, or permanent AF) accurately in the ARIC study,
we did not assess the relationship between AF type and cognitive decline or SCIs. Finally,
information on warfarin use from the study visits and annual follow-up phone calls may not
be complete.
Our findings have important clinical and public health implications. Since the majority of
our participants with AF do not meet criteria for anticoagulation (based on CHADS2) to
prevent stroke, our findings raise 2 questions: First, should patients with AF be
anticoagulated to prevent cognitive decline, even if they don’t meet criteria for
anticoagulation to prevent stroke? Second, should persons with SCIs, irrespective of AF, be
prescribed antiplatelet agents or anticoagulants to prevent cognitive decline? In addition,
since more participants with AF met definite criteria for anticoagulation based on
CHA2DS2–VASc (58.3% of participants with AF had CHA2DS2–VASc score ≥2) than
CHADS2 (10.4% of participants with AF had a CHADS2 score of ≥2), the CHA2DS2–VASc
score may be a more appropriate tool for ascertaining need for anticoagulation in AF. These
questions will need to be addressed in other prospective studies and clinical trials.
In conclusion, in a large biracial population based-cohort study of middle-aged individuals
without stroke, incident AF is independently associated with greater cognitive decline. This
association can be explained by the presence or development of SCIs. Presently,
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anticoagulation is indicated in most patients with AF to prevent thromboembolic stroke.37 In
AF patients without risk factors for stroke (and hence without current indication for
anticoagulation), further research is needed to evaluate whether anticoagulation would be
beneficial in preventing cognitive decline.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Baseline Characteristics by Atrial Fibrillation Status, Atherosclerosis Risk in Communities Study, 1993–2006
Incident AF through 2006
Total sample (n=935) No (n=887) Yes (n=48)
Age, mean (SD), years 61.5 (4.3) 61.4 (4.3) 63.2 (4.3)
Female 62.0 62.5 54.2
Black race 50.7 51.1 43.8
Educational level
 <High school 19.3 18.7 29.2
 Completed high school 33.4 33.6 29.2
 Some college 47.4 47.7 41.7
Cigarette smoking
 Current 13.2 12.5 27.1
 Former 38.3 38.2 39.6
 Never 49.5 49.3 33.3
Body mass index, mean (SD), kg/m2 27.8 (4.8) 27.8 (4.8) 27.8 (5.5)
Diabetes 13.3 13.2 14.6
Hypertension 42.9 42.3 54.2
Coronary heart disease 2.7 2.3 10.4
Heart failure 0.11 0.11 0
Data are presented as percentage of column unless otherwise stated.
AF, atrial fibrillation; SD, standard deviation
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Table 2
Change in Cognitive Test Scores by Atrial Fibrillation Status, Atherosclerosis Risk in Communities Study,
1993–2006
AF x Time
No (n=887) Yes (n=48) P Value
Delayed Word Recall
Model 1* [Referent] 0.07 (−0.09 to 0.24)‡ 0.38
Model 2† [Referent] 0.08 (−0.09 to 0.24)‡ 0.35
Digit Symbol Substitution
Model 1* [Referent] −0.77 (−1.55 to 0.01)‡ 0.05
Model 2† [Referent] −0.77 (−1.55 to 0.01)‡ 0.05
Word Frequency
Model 1* [Referent] −0.78 (−1.58 to 0.01)‡ 0.06
Model 2† [Referent] −0.80 (−1.60 to −0.01)‡ 0.05
AF, atrial fibrillation.
*
Mixed-effects linear model adjusted for age, sex, race, and interactions of age x time, sex x time, and race x time.
†
Mixed-effects linear model additionally adjusted for field center, educational level, and time-varying smoking status, body mass index,
hypertension, diabetes, coronary heart disease, and heart failure.
‡
Difference (95% CI) in annual average rate of change in cognitive test scores associated with AF.
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Table 3
Change in Cognitive Test Scores by Atrial Fibrillation Status in Participants Without Subclinical Cerebral
Infarcts at Baseline (Visit 3) and During Follow-Up, Atherosclerosis Risk in Communities Study, 1993–2006
AF x Time
No (n=670) Yes (n=29) P Value
Delayed Word Recall
Model 1* [Referent] 0.21 (−0.02 to 0.44)‡ 0.07
Model 2† [Referent] 0.20 (−0.03 to 0.43)‡ 0.09
Digit Symbol Substitution
Model 1* [Referent] −0.23 (−1.30 to 0.84)‡ 0.67
Model 2† [Referent] −0.37 (−1.44 to 0.69)‡ 0.49
Word Frequency
Model 1* [Referent] 0.25 (−0.90 to 1.40)‡ 0.67
Model 2† [Referent] 0.10 (−1.04 to 1.25)‡ 0.86
AF, atrial fibrillation.
*
Mixed-effects linear model adjusted for age, sex, race, and interactions of age x time, sex x time, and race x time.
†
Mixed-effects linear model additionally adjusted for field center, educational level, and time-varying smoking status, body mass index,
hypertension, diabetes, coronary heart disease, and heart failure.
‡
Difference (95% CI) in annual average rate of change in cognitive test scores associated with AF.
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Table 4
Change in Cognitive Test Scores by Atrial Fibrillation Status in Participants With Subclinical Cerebral
Infarcts at Baseline (Visit 3), Brain Ancillary Atherosclerosis Risk in Communities Study, 1993–2006
AF x Time
No (n=64) Yes (n=3) P Value
Delayed Word Recall
Model 1* [Referent] −0.10 (−0.50 to 0.31)‡ 0.63
Model 2† [Referent] −0.11 (−0.53 to 0.30)‡ 0.59
Digit Symbol Substitution
Model 1* [Referent] −1.03 (−3.28 to 1.23)‡ 0.37
Model 2† [Referent] −0.97 (−3.21 to 1.27)‡ 0.39
Word Frequency
Model 1* [Referent] −2.69 (−4.29 to −1.08)‡ 0.001
Model 2† [Referent] −2.65 (−4.26 to −1.03)‡ 0.002
AF, atrial fibrillation.
*
Mixed-effects linear model adjusted for age, sex, race, and interactions of age x time, sex x time, and race x time.
†
Mixed-effects linear model additionally adjusted for field center, educational level, and time-varying smoking status, body mass index,
hypertension, diabetes, coronary heart disease, and heart failure.
‡
Difference (95% CI) in annual average rate of change in cognitive test scores associated with AF.
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Table 5
Change in Cognitive Test Scores by Atrial Fibrillation Status in Participants With Development of Subclinical
Cerebral Infarcts During Follow-Up, Atherosclerosis Risk in Communities Study, 1993–2006
AF x Time
No (n=153) Yes (n=16) P Value
Delayed Word Recall
Model 1* [Referent] 0.01 (−0.30 to 0.32)‡ 0.96
Model 2† [Referent] 0.03 (−0.28 to 0.35)‡ 0.83
Digit Symbol Substitution
Model 1* [Referent] −1.59 (−3.07 to −0.10)‡ 0.04
Model 2† [Referent] −1.51 (−3.02 to −0.01)‡ 0.05
Word Frequency
Model 1* [Referent] −1.04 (−2.48 to 0.39)‡ 0.15
Model 2† [Referent] −1.04 (−2.50 to 0.42)‡ 0.16
AF, atrial fibrillation.
*
Mixed-effects linear model adjusted for age, sex, race, and interactions of age x time, sex x time, and race x time.
†
Mixed-effects linear model additionally adjusted for field center, educational level, and time-varying smoking status, body mass index,
hypertension, diabetes, coronary heart disease, and heart failure.
‡
Difference (95% CI) in annual average rate of change in cognitive test scores associated with AF.
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Table 6
Change in Cognitive Test Scores by Subclinical Cerebral Infarct Status Stratified by Atrial Fibrillation,
Atherosclerosis Risk in Communities Study, 1993–2006
Prevalent or incident SCI SCI x Time
No incident AF No (n=670) Yes (n=217) P Value
 Delayed word recall Model 1* [Referent] −0.004 (−0.03 to 0.02)† 0.76
 Digit symbol substitution Model 1* [Referent] −0.14 (−0.24 to −0.03)† 0.008
 Word frequency Model 1* [Referent] 0.02 (−0.08 to 0.12)† 0.71
Incident AF No (n=29) Yes (n=19)
 Delayed word recall Model 1* [Referent] −0.07 (−0.15 to 0.01)† 0.09
 Digit symbol substitution Model 1* [Referent] −0.13 (−0.54 to 0.27)† 0.52
 Word frequency Model 1* [Referent] −0.25 (−0.71 to 0.21)† 0.29
AF, atrial fibrillation; SCI, subclinical cerebral infarct
*
Mixed-effects linear model adjusted for age, sex, race, and interactions of age x time, sex x time, and race x time.
†
Difference (95% CI) in annual average rate of change in cognitive test scores associated with SCI.
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